Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016
NEW DRUG COMBINATION DEMONSTRATES ACTIVITY AGAINST ACINETOBACTER BAUMANNII, A MULTI-DRUG
RESISTANT PATHOGENAND A GLOBAL HEALTH THREAT
WALTHAM, Mass. — June 28, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that preclinical data on ETX2514, a next-generation beta-lactamase inhibitor with a novel mode-of-action and expanded spectrum of antimicrobial activity, were presented at the first annual American Society for Microbiology (ASM) Microbe 2016 conference held in Boston.
Entasis scientists presented the activity of ETX2514 against multiple beta-lactamases and penicillin binding proteins, demonstrating potent inhibition of Class A, C and a broad spectrum of Class D beta-lactamases, important targets in the prevention of bacterial resistance. The results demonstrate restoration of antimicrobial activity in combination with various beta-lactams against Gram-negative, multi-drug resistant (MDR) pathogens, including against MDR and extensively drug resistant (XDR) Acinetobacter baumannii, a significant public health concern which is classified as a serious threat pathogen in the Centers for Disease Control and Prevention’s “Antibiotic Resistance Threats” report.
In a second presentation, Entasis scientists described the further evaluation of the therapeutic potential of ETX2514 and sulbactam in animal infection models of MDR A. baumannii. Different dosing regimens of these agents were investigated to identify appropriate concentrations of both ETX2514 and sulbactam required for robust antimicrobial efficacy. Overall results suggest that the administration of sulbactam in combination with ETX2514 has the potential to be an effective treatment for infections caused by MDR and XDR A. baumannii.
“Our discovery and preclinical development of ETX2514 as a next-generation beta-lactamase inhibitor with a novel mode-of-action and potent activity again Class A, C and a broad spectrum of Class D beta-lactamases, demonstrates the continued progression of Entasis’s robust pipeline,” said Manos Perros, Ph.D., President and Chief Executive Officer of Entasis. “The data presented provides evidence of ETX2514 as a potential therapy against Gram-negative infections, including those caused by A. baumannii. These infections represent an area of significant unmet need, because increased drug resistance has eroded the effectiveness of many treatment options. We plan to advance this program into the clinic by year end, with the goal of introducing this product into the market to address the significant treatment gap that exists today.”
ETX2514 is a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases. Acinetobacter baumannii is a Gram-negative bacterium that causes severe infections which are associated with high mortality. A. baumannii infections are frequently multi-drug resistant and there is an urgent need to identify new agents to treat these infections. Sulbactam is a beta-lactam antimicrobial which has intrinsic activity against A. baumannii, but beta-lactamase-mediated resistance to sulbactam is now widespread. In preclinical studies, ETX2514 restores sulbactam’s antimicrobial activity. Entasis Therapeutics is developing the combination of sulbactam and ETX2514 for the treatment of severe A. baumannii infections.
About Entasis Therapeutics Inc.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of fundamentally innovative clinical and preclinical anti-infective programs is designed to revolutionize the way physicians treat serious bacterial diseases. www.entasistx.com
Company Contact Media Contact
Christopher White Heather Savelle
Chief Business Officer, Entasis Therapeutics MacDougall Biomedical Communications
(781) 810-0114 (781) 235-3060